To observe the tumor-inhibitory effect of Yangfei Kongliu Fang and its effect on the expression of serum IL-2 and TNF-α in mouse models with advanced Lewis lung carcinoma. Methods:By using Lewis lung carcinoma cell suspensions via intrapleural injection, 30 male C57BL/6 mice were prepared into mouse models with advanced Lewis lung carcinoma. After model establishment, the mice were randomly divided into 6 groups: normal saline group (group C/control group), cisplatin group (DDP group), group treated with an equivalent dose of Chinese medicinals (group L), group treated with a high dose of Chinese medicinals (group H), group treated with cisplatin+equivalent dose of Chinese medicinals (group L+DDP), and group treated with cisplatin+high dose of Chinese medicinals (group H+DDP). Each group contained 5 mice and underwent corresponding intervention. Then, the tumor inhibition rate in each group was calculated, and the ELISA method was used to measure the expression of serum IL-2 and TNF-α. Results:The tumor inhibition rates in the DDP group, group L, group H, group L+DDP and group H+DDP were 57.52%, 30.88%, 51.15%, 67.73% and 82.75%, respectively. Compared with the control group, each treatment group achieved significant decreases in the levels of serum IL-2 and TNF-α (P<0.05); and in group H+DDP as compared with DDP group, there were significant decreases in the levels of serum IL-2 and TNF-α (P<0.01). Conclusion:Yangfei Kongliu Fang can inhibit tumor growth and can cooperate with cisplatin to reduce the expression of serum IL-2 and TNF-α in mouse models with advanced Lewis lung carcinoma.